Amin Sharifan, PharmD

Li, S.; Zhang, L.; Wang, Y.; Xie, R.; Chen, W.; Soo Lee, M.; Amer, Y.S.; Sharifan, A.; Hussein, H.; Li, H. (2025). Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study. Frontiers in Pharmacology, 16:1501634: 10.3389/fphar.2025.1501634

Sharifan, A. (2025). Oncolytic Virotherapy in Otorhinolaryngologic Neoplasms: A Scoping Review and Bibliometric Analysis. American Journal of Therapeutics, 10.1097/MJT.0000000000001876: 10.1097/MJT.0000000000001876

Sharifan, A.; Abdulazeem, H.; Meckawy, R.; Sonkoue Pianta, M.; Abdelwahab, M.M.; Halder, A.; Gust Duque, T.; (2025). Appraisal of World Health Organization guidelines for priority infectious diseases with potential to cause public health emergencies. Public Health, 240: 112-118

Sharifan, A. (2025). How does uterine curettage (with or without subsequent adjuvant chemotherapy) compare with primary chemotherapy alone for women with post-molar low-risk, non-metastatic gestational trophoblastic neoplasia? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4514: https://doi.org/10.1002/cca.4514

Sharifan, A. (2025). How does continuous infusion compare with bolus injection of furosemide for adults with acute decompensated heart failure? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4455: https://doi.org/10.1002/cca.4455

Sharifan, A. (2025). How does the addition of immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy compare with platinum-based chemotherapy alone as a first-line treatment for older adults with non-small cell lung cancer (NSCLC)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4509: https://doi.org/10.1002/cca.4509

Sharifan, A. (2025). What are the benefits and harms of classical psychedelics (psilocybin and LSD) for treating anxiety, depression, and existential distress in people with life-threatening diseases? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4512: https://doi.org/10.1002/cca.4512

Sharifan, A. (2025). Can smoking cessation interventions initiated during hospitalization help adults admitted for medical or surgical care to quit smoking? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4529: https://doi.org/10.1002/cca.4529

Sharifan, A.; (2025). What are the effects of disulfiram for adults with cocaine dependence? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4524: https://doi.org/10.1002/cca.4524

GBD 2021 Antimicrobial Resistance Collaborators; Sharifan, A. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459: p1199-1226

GBD 2021 Diarrhoeal Diseases Collaborators; Sharifan, A. (2024). Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect Dis, Published Online: https://doi.org/10.1016/ S1473-3099(24)00691-1

GBD 2021 HIV Collaborators; Sharifan, A. (2024). Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. The Lancet HIV, 11, Issue 12: e807-e822

GBD 2021 Stroke Risk Factor Collaborators; Sharifan, A. (2024). Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology, Volume 23, Issue 10: 973 - 1003

GBD 2021 Tobacco Forecasting Collaborators; Sharifan, A. (2024). Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Public Health, Volume 9, Issue 10,: e729 - e744

GBD 2021 US Obesity Forecasting Collaborators; Sharifan, A. (2024). National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050. The Lancet, 404: 2278-98

GBD 2021 US Obesity Forecasting Collaborators; Sharifan, A. (2024). Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021. The Lancet, 404: 2341-70

GBD 2021 Upper Respiratory Infections Otitis Media Collaborator; Sharifan, A. (2024). Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis, Published Online: https://doi.org/10.1016/S1473-3099(24)00430-4

Kontor, E.K.; Wellan, C.; Mohammad Maaz, H.; Garba Muhammad, D.; Al-Qiami, A.; Sharifan, A.; Kumah, J.; Lacey, H.; Siddiq, A.; Jain, N. (2024). Emerging Therapeutic Modalities and Pharmacotherapies in Neuropathic Pain Management: A Systematic Review and Meta- Analysis of Parallel Randomized Controlled Trials. Pain Research and Management, 6782574: https://doi.org/10.1155/prm/6782574

Sharifan, A. (2024). What are the effects of vitamin D in the management of chronic obstructive pulmonary disease (COPD)? Cochraine Library: Cochrane Clinical Answers, https://doi.org//10.1002/cca.4506: https://doi.org/10.1002/cca.4506

Sharifan, A. (2024). Adherence to Reporting Guidelines: Recommendation or Requirement? American Journal of Therapeutics, 10.1097: 10.1097/MJT.0000000000001822